Study Shows Presence of Cocaine-Like Substance in E-cigarettes in Brazil

Aug.16.2024
Study Shows Presence of Cocaine-Like Substance in E-cigarettes in Brazil
Preliminary research by UFSC and SC police reveals e-cigarettes in Brazil contain dangerous substances similar to methamphetamine.

According to a recent report by Brazilian media outlet Band.uol, a preliminary study conducted by the Federal University of Santa Catarina in collaboration with the state scientific police revealed the presence of a substance similar to amphetamines - octodrine, in e-cigarettes.


According to information released by Santa Catarina Federal University, traces of cocaine were found in three different brands of e-cigarettes collected from ten different samples in the northern city of Joinville in that state. The records also show that these samples contain ingredients such as glycerin, flavorings, and nicotine.


The study also found that the presence of synthetic drugs in the samples may lead to serious poisoning, dependence, withdrawal symptoms, and adverse cardiovascular effects similar to those of synthetic drugs such as methamphetamine acting on the central nervous system.


However, the Santa Catarina State Public Safety Department stated that the presence of cocaine was not indicated on the package label for sale.


The study also emphasizes that exposure of spices to high temperatures may generate harmful substances, particularly more evident with long-term use.


Furthermore, the research also indicates that e-cigarette users have nicotine levels three to six times higher than traditional cigarette smokers.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Japan Tobacco seeks retail price hike for Ploom tobacco sticks; EVO and others to rise by 30 yen per pack
Japan Tobacco seeks retail price hike for Ploom tobacco sticks; EVO and others to rise by 30 yen per pack
Japan Tobacco (JT) said it has applied to raise retail prices for its heated tobacco-related products from April 1, 2026, covering 37 variants of Ploom tobacco sticks and with capsules, with most increases at 20–30 yen per pack (about $0.13–$0.19).
Jan.28 by 2FIRSTS.ai
BAT Japan rolls out limited-edition “Rose Quartz” colourway for glo Hilo, launches new virto click-capsule flavour
BAT Japan rolls out limited-edition “Rose Quartz” colourway for glo Hilo, launches new virto click-capsule flavour
British American Tobacco (BAT) Japan will introduce its first Valentine’s-season limited-edition colourway, “Rose Quartz,” for the glo Hilo heated tobacco device lineup, covering both the glo Hilo and glo Hilo Plus. The devices are priced at JPY 3,980 (about $25.2) and JPY 6,980 (about $44.1), respectively, and will go on sale via official channels from Feb. 9. BAT Japan will also launch a new glo Hilo-compatible virto tobacco stick variant, “virto Bright Cherry Click,” on Feb. 2.
Jan.20 by 2FIRSTS.ai
Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review
Exclusive: Altria Confirms FDA Grants Marketing Authorization to on! PLUS, Ending More Than a Year of PMTA Review
Altria on December 19 confirmed that six on! PLUS nicotine pouch products had received U.S. FDA marketing authorization, ending a PMTA review lasting more than a year after the company moved ahead with launch plans before clearance.
Regulations
Dec.20
Surrey councillor calls for tougher vape sales controls, seeking the “most restrictive legally supportable” package
Surrey councillor calls for tougher vape sales controls, seeking the “most restrictive legally supportable” package
Surrey Councillor Gordon Hepner presented a notice of motion calling on council to “wage war on vaping” by strengthening controls on the sale of vaping products in the city, citing vaping as a “serious health concern,” especially among youth. Hepner said the motion directs staff to bring back the “most restrictive legally supportable” package from the City’s 2019 bylaw work to materially reduce where and how vape products can be sold, including licensing controls and enforcement.
Feb.10 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11